Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing.
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of
Apogee Therapeutics (NASDAQ:APGE – Free Report) had its price target hoisted by Stifel Nicolaus from $46.00 to $95.00 in a research report report published on Tuesday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock. Other equities research analysts have also recently issued reports about the company. BTIG Research started coverage […]
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has received an average rating of “Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in […]
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have earned an average recommendation of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the […]